Overview
Oncotherics Poland is focused on developing next-generation prodrugs that target hypoxic micro-environments in tumors, which are often resistant to conventional cancer treatments. The company has two novel assets: OCT1004, ready for Phase II trials in pancreatic cancer, and OCT1002, in late preclinical phase. They aim to combine these treatments with existing therapies to enhance effectiveness across the entire tumor.
Financials
The financial statement for 2025 has not yet been filed with the Financial Document Repository (past deadline).
Revenue history (in k)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2024.
Results vs industry
News
Industry
Bank accounts
Registered as a VAT taxpayer on 2019-12-01. Active
34 1090 2053 0000 0001 4406 1383- 29 1090 2053 0000 0001 4361 9832
- 10 1090 2053 0000 0001 4655 8013
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
Public aid
6 public aid cases recorded, with a total value of $2,977,240.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 20, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $5,075$5,075 | Prezes Zakładu Ubezpieczeń Społecznych | |
| May 30, 2020 | Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts | $3,823$3,823 | Prezes Zakładu Ubezpieczeń Społecznych | |
| Nov 5, 2019 | Aid for research and development projects: industrial research | $2.1M$2,095,722 | Marszałek Małopolski |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2019-09-25 | ROZWÓJ INNOWACYJNEJ SUBSTANCJI AKTYWOWANEJ HIPOKSJĄ W TERAPII NOWOTWORÓW | $3.1M$3,051,740 | Regionalny Program Operacyjny Województwa Małopolskiego na lata 2014-2020 |
Tenders
No recorded participation in tenders.
Authorized Representatives
Manner of representation
Each member of the management board is authorized to perform legal acts and submit declarations of will on behalf of the company independently.
Supervisory board
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Biostat Research And Developmentsp. z o.o. | $50,225.77 | biostat.com.pl | ||
| Stenocoatsp. z o.o. | $36,665.21 | stenocoat.com | ||
| CannamedaiS.A. | $28,203.90 | cannamedai.com | ||
| NanovelosS.A. | $24,842.03 | nanovelos.com | ||
| Medaisp. z o.o. | $22,311.83 | medai.pl | ||
| Detoxedsp. z o.o. | $11,972.37 | detoxed.pl | ||
| 4cell TherapiesS.A. | $9,123.06 | 4celltherapies.com | ||
| IncellvuS.A. | $6,985.93 | incellvu.pl | ||
| Poltisssp. z o.o. | $3,843.72 | poltiss.com | ||
| Passio Human Microbiomesp. z o.o. | $1,856.58 | passiohumanmicrobiome.com |
Change history
| Date | Event | |
|---|---|---|
| 2022-03-15 | Share capital change (102,200.00 PLN → 104,649.20 PLN) | |
| 2021-10-27 | Entered in the register |
FAQ
Last updated: 2026-04-01